113 related articles for article (PubMed ID: 30381647)
1. [Epigenetic Regulation of Pharmacokinetic-related Genes in Human Tissues].
Hirota T
Yakugaku Zasshi; 2018; 138(11):1391-1396. PubMed ID: 30381647
[TBL] [Abstract][Full Text] [Related]
2. Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines.
Gotanda K; Hirota T; Saito J; Fukae M; Egashira Y; Izumi N; Deguchi M; Kimura M; Matsuki S; Irie S; Ieiri I
Sci Rep; 2016 Aug; 6():32299. PubMed ID: 27571936
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
Urquhart BL; Ware JA; Tirona RG; Ho RH; Leake BF; Schwarz UI; Zaher H; Palandra J; Gregor JC; Dresser GK; Kim RB
Pharmacogenet Genomics; 2008 May; 18(5):439-48. PubMed ID: 18408567
[TBL] [Abstract][Full Text] [Related]
6. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
7. Studies on the intestinal absorption characteristics of sulfasalazine, a breast cancer resistance protein (BCRP) substrate.
Tomaru A; Morimoto N; Morishita M; Takayama K; Fujita T; Maeda K; Kusuhara H; Sugiyama Y
Drug Metab Pharmacokinet; 2013; 28(1):71-4. PubMed ID: 22785334
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.
Tanaka Y; Kitamura Y; Maeda K; Sugiyama Y
J Pharm Sci; 2015 Sep; 104(9):3039-48. PubMed ID: 25639366
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.
Karibe T; Hagihara-Nakagomi R; Abe K; Imaoka T; Mikkaichi T; Yasuda S; Hirouchi M; Watanabe N; Okudaira N; Izumi T
Pharm Res; 2015 May; 32(5):1634-47. PubMed ID: 25380981
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
[TBL] [Abstract][Full Text] [Related]
11. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
12. Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.
Kashihara Y; Ieiri I; Yoshikado T; Maeda K; Fukae M; Kimura M; Hirota T; Matsuki S; Irie S; Izumi N; Kusuhara H; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2688-2694. PubMed ID: 28322941
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of drug transporter expression in human tissues.
Hirota T; Tanaka T; Takesue H; Ieiri I
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):19-30. PubMed ID: 27579666
[TBL] [Abstract][Full Text] [Related]
14. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
15. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
[TBL] [Abstract][Full Text] [Related]
16. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer resistance protein (BCRP/ABCG2).
Staud F; Pavek P
Int J Biochem Cell Biol; 2005 Apr; 37(4):720-5. PubMed ID: 15694832
[TBL] [Abstract][Full Text] [Related]
18. Regulation of BCRP expression and sulfasalazine pharmacokinetics by the nuclear receptor REV-ERBĪ±.
Wu C; Xiao Y; Wu C; Xie D; Luo M; Yao D; Chen M; Lu D
Xenobiotica; 2023 Mar; 53(3):215-222. PubMed ID: 37039301
[TBL] [Abstract][Full Text] [Related]
19. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
20. Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles.
Shi P; Liao M; Chuang BC; Griffin R; Shi J; Hyer M; Fallon JK; Smith PC; Li C; Xia CQ
Xenobiotica; 2018 Nov; 48(11):1173-1183. PubMed ID: 29098941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
